Danicopan (Voydeya)
Danicopan
Astrazeneca Pharmaceuticals (Pty) Ltd
Registration
- Applicant
- Astrazeneca Pharmaceuticals (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Voydeya 50 MG EACH TABLET CONTAINS: DANICOPAN 50,0 mg | 50 mg | 60050460/8.5/0504 | Registered | Not determined | None |
| Voydeya 100 MG EACH TABLET CONTAINS: DANICOPAN 100,0 mg | 100 mg | 60050560/8.5/0505 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(2S,4R)-1-[2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-4-fluoropyrrolidine-2-carboxamide
Drag to rotate. Structure from PubChem CID 118323590.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.